Results 51 to 60 of about 334,676 (308)

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. [PDF]

, 2012
BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy.
Phillips, AN, Alec Miners, Valentina Cambiano (146513), von Wyl Viktor, Phillips, Andrew N, Andrew N Phillips, Bertagnolio, S, Cambiano, V, Jens Lundgren, Valentina Cambiano, Silvia Bertagnolio, Pillay Deenan, Pillay, Deenan, Deenan Pillay (7888), Bertagnolio, Silvia, Miners Alec, Jordan, MR, Michael R. Jordan (146520), Cambiano, Valentina, von Wyl, Viktor, Viktor von Wyl, Phillips Andrew N., Jordan, Michael R, Cambiano Valentina, Miners, Alec, Pillay, D, Bertagnolio Silvia, Lundgren Jens, Miners, A, Andrew N. Phillips (146556), Lundgren, Jens, Alec Miners (146534), Viktor von Wyl (146506), Silvia Bertagnolio (57174), Michael R Jordan, Deenan Pillay, von Wyl, V, Lundgren, J, Jens Lundgren (146550), Jordan Michael R.   +39 more
core   +1 more source

Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. [PDF]

PLoS ONE, 2015
The emergence of HIV-1 drug resistance mutations has mainly been linked to the duration and composition of antiretroviral treatment (ART), as well as the level of adherence.
Andargachew Mulu, Melanie Maier, Uwe Gerd Liebert   +2 more
doaj   +1 more source

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

FEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? [PDF]

, 2011
Background: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can ...
Braun, Patrick, Ehret Robert, Naeth, Gudrun, Frank Wiesmann, Tappe André, Tappe, André, Rolf Kaiser, Martin Stürmer, Hauke Walter, Jan Vachta, Walter, Hauke, André Tappe, Ehret, Robert, Stürmer Martin, Thomas Berg, Kaiser Rolf, Robert Ehret, Berg Thomas, Naeth Gudrun, Knechten Heribert, Gudrun Naeth, Patrick Braun, Knechten, Heribert, Stürmer, Martin, Wiesmann, Frank, Vachta, Jan, Heribert Knechten, Kaiser, Rolf, Berg, Thomas, Walter Hauke, Martin Däumer, Braun Patrick, Däumer Martin, Wiesmann Frank, Vachta Jan, Däumer, Martin   +35 more
core   +1 more source

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses [PDF]

, 2020
Coronaviridae is a peculiar viral family, with a very large RNA genome and characteristic appearance, endowed with remarkable tendency to transfer from animals to humans.
Alkhatib, M, Ceccherini-Silberstein, Francesca, Santoro, Maria Mercedes, Salpini, Romina, Assaraf, YG, Assaraf, Yehuda G, Artese, Anna, Santoro, Maria, Assaraf, Yehuda G., Ambrosio, FA, Artese, A, Salpini, R, Svicher, V, Costa, G, Di Maio, Velia Chiara, Di Maio, VC, Alcaro, Stefano, Alkhatib, Mohammad, Ambrosio, Francesca Alessandra, Santoro, MM, Costa, Giosuè, Alcaro, S, Svicher, Valentina, Ceccherini-Silberstein, F   +23 more
core   +1 more source

Dominant drug targets suppress the emergence of antiviral resistance

eLife, 2014
The emergence of drug resistance can defeat the successful treatment of pathogens that display high mutation rates, as exemplified by RNA viruses.
Elizabeth J Tanner, Hong-mei Liu, M Steven Oberste, Mark Pallansch, Marc S Collett, Karla Kirkegaard   +5 more
doaj   +1 more source

Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research

Scientific Reports, 2023
There has been a surge in the emergence of HIV-1 drug resistance in Low and Middle-Income Countries (LMICs) due to poor drug-adherence and limited access to viral load testing, the current standard for treatment-monitoring.
Jemima Malisa, Mark Manak, Clive Michelo, Nesrina Imami, Catherine N. Kibirige   +4 more
doaj   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Population-Wide Emergence of Antiviral Resistance during Pandemic Influenza

, 2008
Background: The emergence of neuraminidase inhibitor resistance has raised concerns about the prudent use of antiviral drugs in response to the next influenza pandemic.
Wu, Jianhong, Röst, Gergely, Moghadas Seyed M., Jianhong Wu, Christopher S Bowman, Wu Jianhong, Bowman, Christopher S., Galvani, Alison P., R\uf6st, Gergely, Moghadas, Seyed M., Gergely Röst, Seyed M Moghadas, Bowman Christopher S., Röst Gergely   +13 more
core   +1 more source

The HIV-1 Subtype C Epidemic in South America Is Linked to the United Kingdom [PDF]

, 2010
Background: The global spread of HIV-1 has been accompanied by the emergence of genetically distinct viral strains. Over the past two decades subtype C viruses, which predominate in Southern and Eastern Africa, have spread rapidly throughout parts of ...
Gifford, RJ, Gifford Robert J., Pillay Deenan, Pillay, D, Tulio de Oliveira, UK Collaborative Grp HIV Drug Resi, Robert J Gifford, Deenan Pillay, de Oliveira, T, UK Collaborative Group on HIV Drug Resistance, de Oliveira Tulio   +10 more
core   +1 more source